There are currently 163 active clinical trials seeking participants for Colorectal Cancer research studies. The states with the highest number of trials for Colorectal Cancer participants are California, Illinois, Ohio and New York.
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
NCT05902520
Recruiting
The subject of this study is the adoptive transfer of selected autologous tumor infiltrating lymphocytes (TIL) after in vitro expansion for the treatment of solid tumor malignancies. The TIL selection process is based on evidence showing that CD8+ TIL which co-express both CD39 and CD103 harbor the bulk of tumor-reactivity and that the remaining CD8 TIL is mainly composed of non-tumor reactive bystander cells. All of the expanded TIL that are produced (1-40 billion are expected) will be delivere... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2023
Locations: Providence Portland Medical Center, Portland, Oregon
Conditions: HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer, Lung Cancer, Urogenital Cancer
Register for Updates
Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis
NCT03073694
Recruiting
The purpose of this trial is to compare the morbidity and mortality of CRS-HIPEC using mitomycin-C versus melphalan for colorectal peritoneal carcinomatosis. Morbidity and mortality will measured using the Comprehensive Complication Index (CCI) score, Common terminology criteria for adverse events (CTCAE version 4.03), and the Clavien-Dindo Classification.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/07/2023
Locations: The University of Kansas Medical Center, Westwood, Kansas
Conditions: Cancer, Appendiceal, ColoRectal Cancer
Register for Updates
GCC19CART for Patients With Metastatic Colorectal Cancer
NCT05319314
Recruiting
Study ICT-GCC19CART-US-001 (CARAPIA-1) is a Phase 1 study evaluating the safety, tolerability, clinical activity, pharmacokinetics and pharmacodynamics of GCC19CART in subjects with relapsed or refractory metastatic colorectal cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2023
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +5 locations
Conditions: Colorectal Cancer
Register for Updates
Impact of AI on Trainee ADR
NCT05423964
Recruiting
Adenoma detection rate (ADR) is a validated quality metric for colonoscopy with higher ADR correlated with improved colorectal cancer outcomes. Artificial intelligence (AI) can automatically detect polyps on the video monitor which may allow endoscopists in training to improve their ADR. Objective and Purpose of the study: Measure the effect of AI in a prospective, randomized manner to determine its impact on ADR of Gastroenterology trainees.
Gender:
ALL
Ages:
All
Trial Updated:
03/02/2023
Locations: LAC+USC Medical Center, Los Angeles, California
Conditions: Adenoma, Adenoma Colon, Colorectal Cancer
Register for Updates
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
NCT05210283
Recruiting
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: Providence Facey Medical Foundation, Mission Hills, California +28 locations
Conditions: Colorectal Cancer
Register for Updates
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
NCT05576896
Recruiting
This is a Phase II, open label, single-arm trial study of adding hydroxychloroquine to encorafenib and cetuximab in patients with metastatic BRAF V600E colon cancer with progression on at least 1 prior line of therapy. We hypothesize that autophagy is a major mechanism of resistance to BRAF inhibition in stage IV BRAF V600E colorectal cancer, and that the addition of hydroxychloroquine to standard encorafenib and cetuximab therapy will help overcome this resistance.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/16/2022
Locations: Northwestern University, Chicago, Illinois
Conditions: Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV
Register for Updates
The Genomic Medicine at VA Study
NCT04331535
Recruiting
This trial will determine the clinical effectiveness of polygenic risk score testing among patients at high genetic risk for at least one of six diseases (coronary artery disease, atrial fibrillation, type 2 diabetes mellitus, colorectal cancer, breast cancer, or prostate cancer), measured by time-to-diagnosis of prevalent or incident disease over 24 months.
Gender:
ALL
Ages:
Between 50 years and 70 years
Trial Updated:
09/29/2022
Locations: VA Boston Healthcare System, Boston, Massachusetts
Conditions: Coronary Artery Disease, Atrial Fibrillation, Type 2 Diabetes, Colorectal Cancer, Breast Cancer, Prostate Cancer
Register for Updates